Metagenomi/MGX

$6.64

-7.39%
-
1D1W1MYTD1YMAX

About Metagenomi

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

Ticker

MGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Thomas

Employees

236

Headquarters

Emeryville, United States

Metagenomi Metrics

BasicAdvanced
$266M
Market cap
-
P/E ratio
-$1.82
EPS
-
Beta
-
Dividend rate
$266M
$12.74
$5.50
129K
4.041
5.945
1.236
160.21%
-56.57%

What the Analysts think about Metagenomi

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
186.14% upside
High $25.00
Low $10.00
$6.64
Current price
$19.00
Average price target

Metagenomi Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-156.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$12M
0%
Net income
-$19M
-3.03%
Profit margin
-156.09%
-3.03%

Metagenomi Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 53.22%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$1.19
-
Expected
-$0.78
-$0.64
Surprise
53.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Metagenomi stock?

Metagenomi (MGX) has a market cap of $266M as of May 24, 2024.

What is the P/E ratio for Metagenomi stock?

The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of May 24, 2024.

Does Metagenomi stock pay dividends?

No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of May 24, 2024.

When is the next Metagenomi dividend payment date?

Metagenomi (MGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Metagenomi?

Metagenomi (MGX) does not currently have a Beta indicator.

What is the Metagenomi stock price target?

The target price for Metagenomi (MGX) stock is $19, which is 186.14% above the current price of $6.64. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Metagenomi stock

Buy or sell Metagenomi stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing